Product

Anti PD1

Aliases

anti PD1 drug

1 clinical trial

1 indication

Indication

Advanced/Metastatic Solid Tumors

Clinical trial

A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG116, ADG116 Combined With Toripalimab (Anti-PD-1 Antibody), ADG116 Combined With ADG106 (Anti-CD137 Antibody) in Patients With Advanced/Metastatic Solid Tumors

Status: Active (not recruiting), Estimated PCD: 2024-07-01